Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Regulatory News (SYNC)

Share Price Information for Syncona (SYNC)

Share Price is delayed by 15 minutes
Get Live Data
96.20    0.20 (0.21%)
Bid:
96.60
Ask:
97.70
Spread: 1.10 (1.139%)
Market Cap: £585.08m
SYNC Live PriceLast checked at - London Stock Exchange

Intraday Syncona Share Chart

Director Changes

10 Sep 2015 17:43

BACIT LIMITED - Director Changes

BACIT LIMITED - Director Changes

PR Newswire

London, September 10

BACIT Limited (the "Company")

(a closed-ended collective investment scheme established as a company with limited liability under the laws of Guernsey with registered number 55514)

Director Resignation & Appointment

10 September 2015

The Company announces the resignation of Jonathan Moulton as a non-executive independent director of the Company and the appointment of Arabella Cecil as a non-executive director of the Company, both effective 9 September 2015.

The Board of Directors wish to thank Mr Moulton for his contribution to the Company and welcome Ms Cecil. 

Company website: www.bacitltd.com

Enquiries:Northern Trust International Fund Administration Services (Guernsey) LimitedEmail: rb235@ntrs.comTel: +44 (0) 1481 745189 

Date   Source Headline
30th May 202312:44 pmRNSFreeline reports Q1 2023 Financial Results
19th May 202311:00 amRNSNotice of Results
15th May 20233:16 pmRNSHolding(s) in Company
12th May 202311:14 amRNSHolding(s) in Company
10th May 202312:20 pmRNSAchilles reports Q1 2023 Financial Results
4th May 202312:05 pmRNSAutolus reports Q1 2023 Financial Results
24th Apr 20233:09 pmRNSHolding(s) in Company
19th Apr 20234:57 pmRNSHolding(s) in Company
4th Apr 202312:05 pmRNSFreeline reports Full Year 2022 Financial Results
4th Apr 202312:05 pmRNSSyncona expands portfolio with £22.5m Series A
13th Mar 20237:00 amRNSUpdate re. Silicon Valley Bank
7th Mar 202312:05 pmRNSAchilles reports Q4 and full year 2022 Results
7th Mar 202312:05 pmRNSAutolus reports full year 2022 Financial Results
7th Feb 20237:00 amRNSThird Quarter Update
22nd Dec 20227:00 amRNSAutolus announces partial exercise of ADS option
12th Dec 20223:05 pmRNSAutolus presents clinical data updates at ASH
9th Dec 20227:00 amRNSAutolus announces pricing of public offering
9th Dec 20227:00 amRNSFELIX trial of obe-cel meets its primary endpoint
6th Dec 202211:05 amRNSAchilles presents clinical data update
1st Dec 20227:19 amRNSAchilles to present clinical data update
1st Dec 20227:00 amRNSSyncona completes acquisition of AGTC
29th Nov 20227:14 amRNSNeogene to be acquired by AstraZeneca
29th Nov 20227:00 amRNSSyncona extends tender offer for AGTC
17th Nov 20227:00 amRNSHalf-year Report
15th Nov 202212:05 pmRNSFreeline reports Q3 2022 Financial Results
10th Nov 20222:05 pmRNSAnaveon presents updated data from ANV419
8th Nov 202212:05 pmRNSAchilles reports Q3 2022 Financial Results
3rd Nov 20221:39 pmRNSAutolus to present clinical data updates at ASH
3rd Nov 202211:05 amRNSAutolus Reports Q3 2022 Financial Results
27th Oct 20222:58 pmRNSNotice of Results
24th Oct 20227:00 amRNSSyncona to acquire AGTC
12th Sep 20227:00 amRNSAnaveon presents updated ANV419 data
17th Aug 202210:00 amRNSApplication for admission of shares to listing
16th Aug 20227:00 amRNS1st Quarter Results
9th Aug 202212:05 pmRNSAchilles reports Q2 2022 Financial Results
9th Aug 202212:05 pmRNSFreeline reports Q2 2022 Financial Results
4th Aug 202212:07 pmRNSAutolus Reports Q2 2022 Financial Results
3rd Aug 20221:15 pmRNSHolding(s) in Company
2nd Aug 202212:28 pmRNSResult of AGM
2nd Aug 20227:00 amRNSTotal Voting Rights
15th Jul 20227:00 amRNSIssue of shares pursuant to incentive scheme
11th Jul 20227:00 amRNSFreeline presents data in haemophilia B
7th Jul 20229:41 amRNSHolding(s) in Company
30th Jun 20229:00 amRNSPublication of 2022 Annual Report & Notice of AGM
22nd Jun 20225:21 pmRNSDirector Declaration
16th Jun 20227:00 amRNSFinal Results
10th Jun 20228:05 amRNSAutolus presents clinical data updates at EHA
8th Jun 20222:33 pmRNSHolding(s) in Company
19th May 20227:00 amRNSNotice of Results
18th May 202211:05 amRNSSyncona invests in $56 million SwanBio Series B

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.